On September 15, 2025, X4 Pharmaceuticals announced a major restructuring plan including a 50% workforce reduction expected to save approximately $13 million annually, with a one-time cost of about $3.3 million for severance. This event is significant for investors as it aims to focus resources on completing critical clinical trials.